October 10, 2024 10:40 PM EDTUpdated 06:31 AM
R&D

Sanofi dis­con­tin­ues De­nali-part­nered MS tri­al af­ter Phase 2 fail­ure

Max Bayer

Pharma Reporter

Sanofi is end­ing a Phase 2 clin­i­cal tri­al that’s test­ing a drug from De­nali for mul­ti­ple scle­ro­sis, putting a stop to the de­vel­op­ment plan. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times